Zobrazeno 1 - 6
of 6
pro vyhledávání: '"M C, de Gracia"'
Autor:
M, Molina, M J, Navarro, M E, Palacios, M C, de Gracia, M A, García Hernández, F, Ríos Moreno, F M, Pérez Silva
Publikováno v:
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 27(2)
Chronic inflammatory diseases and infections are a major cause of hyporesponse to erythropoiesis-stimulating factors. We conducted this prospective study in 107 patients in haemodialysis with dialysis liquid that was potentially contaminated from a b
Publikováno v:
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 25(5)
This randomized, prospective, two-arm clinical study evaluated the antiproteinuric and nephroprotective effects and the safety of treatment with an angiotensin II receptor antagonist (irbesartan) in patients with chronic glomerulonephritis (CGN) as c
Publikováno v:
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 24(6)
This prospective, two-arm, clinical trial assesses the effectiveness in maintaining the levels of haemoglobin (Hb) between 11 and 13 g/d1 and the safety of changing the administration route (from subcutaneous to intravenous) of epoetin (rHuEPO) alpha
Publikováno v:
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 24(1)
Darbepoetin alfa is an erythropoiesis-stimulating glycoprotein with up to 3 times longer half-life than recombinant human erythropoietin (rHuEPO) in humans. The aim of this study was to assess the efficacy and safety of darbepoetin alfa given once ev
Publikováno v:
Atencion primaria. 23(1)
To quantify the primary care demand for laboratory tests in a health area and to evaluate the variations in use in relation to the characteristics of the doctors, of organisation and of the population seen.Crossover.A health area in the Community of
Publikováno v:
Medicina clinica. 96(16)